In March 2004 when Sanofi-Aventis SA reported data on their “miracle” obesity drug, it attracted instant attention. To date, however, the drug has not hit the U.S. market. The FDA has asked for more research and has delayed approval for the drug as an obesity treatment and rejected it for smoking cessation. The side effects associated with the drug Acomplia include depression and anxiety and are giving the FDA cause for concern. The FDA has a meeting scheduled for June 13 to review Acomplia, which could be a precursor to a final decision.
For the full article.